While urolithin A may be able to promote better mitochondrial health by supporting mitophagy,7 there currently isnt any research to suggest that the compound could benefit primary or genetic mitochondrial diseases (e.g., Leigh syndrome, Kearns-Sayre syndrome, Leber hereditary optic neuropathy, etc.).16 Some experts suggest that it could be worth investigating whether mitophagy activation could act as a novel strategy to treat these diseases, but that research hasnt been conducted yet.17 18 19 When that happens, well update this information
Therefore, the purpose of this scoping review is to characterize the current evidence base for peptide therapies relevant to musculoskeletal care, with emphasis on BPC-157, thymosin beta-4 derivatives, and related agents, and to define safety considerations and perioperative implications for orthopaedic surgical patients, including those undergoing TJA
The published evidence does not show any of the following: That CagriSema is superior or inferior to tirzepatide no head-to-head trial exists, so the near-identical weight numbers cannot be turned into a ranking
Also, learn if collagen is as good as whey for muscle maintenance
9, ZE21ZE25